15 results about "Promoter methylation" patented technology

The invention discloses TCN1 (Trancobalamin 1, cobalamin 1) and application of an inhibitor of the TCN1 in preparation of products for diagnosing and treating diseases of an autoimmune system. According to the invention, expression in psoriasis tissues is up-regulated and promoter DNA methylation is down-regulated into genes to screen TCN1 genes, an over-expression TCN1 HaCaT cell line is constructed, and it is verified that the over-expression TCN1 HaCaT cell line participates in keratinocyte proliferation and IL-17 activation as an autoantigen, can be used as a diagnostic marker and a therapeutic target of autoimmune skin diseases such as psoriasis and the like, and has broad application prospects. And a new direction is provided for mechanism research and treatment of autoimmune skin diseases such as psoriasis.

The invention belongs to the technical field of biology, and particularly relates to a construction method of epigenome edited zebrafish, sgRNA of a targeted zebrafish runx2b gene promoter region and application of the sgRNA. The invention provides a construction method of epigenome edited zebrafish, which comprises the step of carrying out methylation editing by using a CRISPR / dCas9-methyltransferase system targeting runx2b gene promoter region, thereby inhibiting runx2b gene expression and reducing intermuscular bone formation. According to the method, the expression level of the runx2b gene is accurately regulated and controlled through an epigenetic editing technology on the premise that a DNA sequence is not changed, and formation of fish intermuscular bones is effectively reduced. The zebra fish F0 treated by the method represents that the runx2b mRNA expression level is obviously reduced, and the intermuscular bones of the eleventh to sixteenth sarcomedo regions of adult F0 generation fish are obviously shorter than those of a control group, and the shortening range reaches 23.3% to 38.8%. Besides, the method provides theoretical basis and technical support for improving fish economic traits by accurately regulating and controlling the expression mode of the key economic trait gene and simultaneously keeping the integrity of genome DNA (Deoxyribose Nucleic Acid).

A method and apparatus for detecting MGMT promoter methylation in glioblastoma, relating to the field of Raman spectroscopic detection. The method comprises: performing Raman spectral scanning on a glioma tissue sample to be detected to obtain Raman spectral data; preprocessing the Raman spectral data to obtain normalized Raman spectral data; extracting intensity values at characteristic shifts from the normalized Raman spectral data; and inputting the intensity values at the characteristic shifts into a classification model to calculate a classification prediction value, the classification prediction value being used for assisting in determining the MGMT promoter methylation state of said glioma tissue sample. The effect of the present application is that low-cost, non-destructive and accurate detection of the MGMT promoter methylation state of glioblastoma can be achieved.

The invention belongs to the technical field of biological medicine, provides a mustard gas immunotoxicity evaluation method based on Foxp3 promoter methylation, and evaluates the application effect of the Foxp3 promoter methylation level in mustard gas immunotoxicity evaluation in combination with in-vitro cell experiments and in-vivo animal experiments. Results show that Treg cell deficiency is a main reason for tissue damage and inflammation caused by mustard gas poisoning, cell fate and functions of the Treg cell deficiency are mainly regulated and controlled by Foxp3 transcription factors, mustard gas can cause increase of the DNA methylation level of Foxp3 gene loci, DNA hypermethylation of Foxp3 promoters is crucial to Treg cell differentiation inhibition, Th17 / Treg imbalance and systemic inflammation caused by mustard gas exposure, and the Treg cell deficiency is a main reason for tissue damage and inflammation caused by mustard gas poisoning. The methylation level of the Foxp3 promoter can be used as a marker of a mustard gas immunotoxicity evaluation method.

This invention provides GW2 The application of gene promoter methylation in regulating rice grain width belongs to the field of genetic engineering technology. This invention is based on the discovery of rice... ddm1 Methylation mutation sites in mutants were successfully identified. GW2 A novel epigenetic allelic variant was discovered. GW2 The DNA methylation status of a segment of the upstream promoter region of a gene corresponds to the grain width phenotype in rice. This invention utilizes an epigenetic editing system to demethylate a hypermethylated region in wide-grained rice, resulting in a significantly reduced grain width phenotype. Therefore, by regulating... GW2 GW2 Gene promoter methylation levels can enable precise regulation of rice grain width traits.

The invention provides an RhAG promoter methylation regulatory protein and application thereof in development regulation of Chinese rose petals. Specifically, the invention provides an RhAG promoter methylation regulatory protein RhDRM2, RhBIM1 or RhBIM2, or a coding nucleotide sequence, an expression vector or a host cell thereof, and application of the RhAG promoter methylation regulatory protein RhDRM2, RhBIM1 or RhBIM2 in Chinese rose petal regulation or RhAG promoter methylation regulation, especially application of the RhAG promoter methylation regulatory protein RhDRM2, RhBIM1 or RhBIM2 in low temperature induction resistance or double petal flower breeding. The invention provides an effective genetic engineering breeding means for low-temperature-resistant variety or double-petal breeding of Chinese rose, and has a wide application prospect.

This specification describes diagnostic methods for selecting treatments for personalized cancer therapy by simultaneously detecting genomic and epigenomic characteristics from a single patient sample, including the quantification of promoter methylation, as well as applications for confirming methylation patterns associated with epigenetic allele status. This specification also describes methods comprising the steps of detecting methylation in one or more promoter regions of at least one of multiple genes, and generating multiple methylation calls to quantify methylation in one or more promoter regions.

This invention belongs to the field of plant genetic engineering technology, specifically involving SsuTDX The application of gene promoter methylation in regulating hemicellulose synthesis. This invention discloses... SsuTDX The application of gene promoter methylation in regulating hemicellulose synthesis, among which SsuTDX The promoter methylation region of the gene has a nucleotide sequence as shown in SEQ ID NO.1. SsuTDX High levels of gene promoter methylation inhibit hemicellulose synthesis; SsuTDX Low methylation levels in the gene promoter promote hemicellulose synthesis. Furthermore, methylation in this region affects SsuMYB295 binding, and temperature can positively regulate methylation levels. This invention provides molecular targets and specific methods for precisely regulating hemicellulose synthesis in *Symplocos edulis*, laying the foundation for targeted breeding of long-fiber varieties, genetic improvement, and material optimization, and has significant practical value.

The invention relates to a reagent for improving the methylation level of a FANCB promoter and application, and particularly provides an epigenetic editing reagent which enables the methylation level of a FANCB promoter region to be increased, so that FANCB is inactivated, and then ovarian cancer is treated and the drug sensitivity of the ovarian cancer is increased.

This invention belongs to the field of biomedical technology, specifically providing the application of TL1A as a biomarker in the diagnosis of cirrhosis. This invention is the first to discover that the TL1A gene promoter exhibits a hypomethylated state in patients with hepatitis B-related cirrhosis, suggesting a close correlation between the methylation level of the TL1A gene promoter and the diagnosis of hepatitis B-related cirrhosis. Therefore, quantitative detection of TL1A gene promoter methylation can indicate the occurrence and progression of hepatitis B-related cirrhosis, thereby assisting in clinical diagnosis and possessing significant practical application value.

In implementations described herein, methylation information is determined with respect to classification regions of a reference genome that are related to the presence of a tumor in a subject. The methylation information can be analyzed using a number of computational techniques to provide metrics related to the presence or absence of a tumor in a given subject, including a determination of tumor fraction.

The application belongs to the technical field of biological detection, and particularly relates to a biomarker composition and application thereof in MGMT promoter methylation detection. The biomarker composition comprises: phospholipids (L5PL) in LDL-5 subcomponent, creatinine, and ornithine. The application uses multiple biomarkers to determine whether a glioblastoma patient carries MGMT promoter methylation, has good sensitivity and specificity, is less traumatic to the patient, can overcome individual differences, and provides a new solution for prognosis evaluation of glioblastoma.

This disclosure relates to DNA-based medical diagnostics, and in particular methods for measuring BRCA1 promoter methylation and model-based estimations for determining the methylation status of cfDNA across multiple genomic loci. In one embodiment, the method comprises measuring a fraction of methylated molecules at a BRCA1 promoter region. In one embodiment, the method includes accessing a cell-free DNA (cfDNA) extracted from a biological sample, generating sequence reads from the cfDNA, and identifying methylation patterns at multiple genomic sites within the cfDNA. In certain embodiment, the method comprises executing machine-learning models on the sequence reads and the identified methylation patterns to estimate a methylation status of a target genomic site. In certain embodiments, the machine-learning models are trained using a set of reference data generated from tissue or plasma samples with identified methylation status at genomic sites.

The invention discloses an application of TBX1 / TBX1 methylation in treatment of esophageal cancer. Researches prove that after TBX1 methylation silencing, the proliferation effect of ESCC cells can be improved, and the drug resistance of cisplatin chemotherapy of the ESCC cells is improved; the treatment effect of cis-platinum in ESCC cells can be remarkably improved by recovering TBX1 expression in vivo and in vitro. In combination with clinical sample analysis, it is found that TBX1 promoter hypermethylation has universality in ESCC platinum chemotherapy tumor-resistant tissue, so that TBX1 promoter methylation can be used as an epigenetic biomarker for predicting ESCC platinum chemotherapy sensitivity, and TBX1 is expected to be used as a platinum-resistant ESCC chemotherapy sensitization target.

The present disclosure provides methods for distinguishing virion DNA from tumor-derived viral DNA within viral nucleic acid sequences by determining a DNA methylation status of the viral nucleic acid sequence. The methods are used for diagnosing and treating cancer. The method of diagnosing a subject with cancer or treating cancer in a subject comprises identifying a viral nucleic acid sequence in a sample as virion DNA or tumor-derived viral DNA including determining a DNA methylation status of the viral nucleic acid sequence. The methylation of the viral nucleic acid sequence is indicative of tumor-derived viral DNA and the absence of methylation of the viral nucleic acid sequence is indicative of virion DNA.